You are viewing the site in preview mode

Skip to main content

Table 2 Characteristics of included clinical studies

From: The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis

References # centres Sample size (control/intervention) Age of cohort (mean, range) % Male (overall) Follow-up Disease status Study design Groups
James et al. [49] NR 29 (10/19) 41 (26–66)†
38 (18–72)‡ 		41 NR In remission Two arm randomized cross-over trial Ulcerative colitis patients (i) High dose RS
(ii) Low dose RS
Healthy controls (i) High dose RS
(ii) Low dose RS
Clarke et al. [48] NR 7 56 (37–81) 14 NR In remission Single arm, cross over Ulcerative colitis & crohn’s disease patients (i) HAMS
(ii) LAMS
(iii) Acetylated HAMS
(iv) Propionylated HAMS
(v) Butyrylated HAMS
Hanai et al. [46] 3 59 (37/22) 40.7 (2.3)†§
42.5 (2.9)ठ		58 NR In remission Two-arm Ulcerative colitis patients GBF-supplemented diet
Regular diet
Hallert [47] 3 32 (10/22) 43 (21–64)†
44 (20–77)‡ 		59 6 months In remission Two-arm Ulcerative colitis patients Oat bran-supplemented diet
Regular diet
Kanauchi [38, 45] 8 21 42.5 (2.9)§ NR NR No change in disease activity for at least 4-weeks prior to trial Single arm Ulcerative colitis patients GBF-supplemented diet
Silvester et al. [43] 1 6 50 (39–59) 17 NR Unclear Randomized single arm, cross over trial Ulcerative colitis patients (i) High RS
(ii) Regular diet
(iii) Potato flour
(iv) Low RS
(v) Medium RS
Mitsuyama et al. [44] 1 10 44.1 (26–67) 50 2 months Unclear single arm Ulcerative colitis patients GBF-supplemented diet
  1. GBF germinated barley foodstuff, HAMS high-amylose maize starch, LAMS low-amylose maize starch, N/A not applicable, NR not reported, RS resistant starch
  2. §Age mean (SEM)
  3. †Age of control group
  4. ‡Age of intervention group
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us